COMMUNIQUÉS West-GlobeNewswire
-
Apollomics Regains Full Compliance with Nasdaq Listing Requirements
13/07/2026 -
Solésence Brings Patent-Backed Skin Health Innovation to Hair and Scalp
13/07/2026 -
NetraMark Engages AM Public Relations to Support Strategic Communications and Market Awareness
13/07/2026 -
Bavarian Nordic’s Chikungunya Vaccine Submitted for Regulatory Approval in Brazil
13/07/2026 -
Picard Medical / SynCardia Releases Annual Stockholder Presentation Ahead of 2026 Annual Meeting
13/07/2026 -
EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer
13/07/2026 -
Enovis™ Companion Animal Health Launches CT-RevitL™, the Next-Generation Laser Therapy System for Veterinary Care
13/07/2026 -
Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio
13/07/2026 -
Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis
13/07/2026 -
Autonomix Medical Strengthens Global Intellectual Property Position with New Neural Sensing Patent Grant
13/07/2026 -
Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development
13/07/2026 -
VitalHub Announces Acquisition of Buddy Healthcare
13/07/2026 -
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
13/07/2026 -
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
13/07/2026 -
REPEAT - Grifols deaths and harm: Patient safety & options for accountability
13/07/2026 -
Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial
13/07/2026 -
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
13/07/2026 -
Geron Announces Appointment of Chinmaya Rath as Chief Business Officer
13/07/2026 -
Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
13/07/2026
Pages